TIVICAY
Pronunciation: doe-loo-TEG-ra-veer (TIV-e-kay)


What it isHIV integrase strand-transfer inhibitor; a preferred anchor for initial and treatment-experienced regimens.
Why this oneIts unusually high barrier to resistance distinguishes it from earlier integrase inhibitors.
What limits itPolyvalent cations block absorption—separate antacids and supplements. It raises creatinine by blocking tubular secretion without lowering GFR; weight gain.
Animated chart of estimated U.S. prescriptions per year, HIV antiretrovirals (1987–2026). Dolutegravir enters in 2013 (estimated).
Principal riskCations block absorption; weight gain
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityAgent-specific renal, hepatic, hematologic, metabolic and drug-interaction toxicity.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| HIV-1 (INSTI-naive or virologically suppressed) | Adults | 50 mg QD | 50 mg QD | 50 mg QD |
| HIV-1 with UGT1A/CYP3A inducers or INSTI resistance | Adults | 50 mg BID | 50 mg BID | 50 mg BID |
| HIV-1 (weight-based, Tivicay PD) | Peds ≥4 wk & ≥3 kg | 5 mg QD (3–<6 kg) | weight-based QD | 30 mg QD (≥20 kg) |
Renal No adjustment for INSTI-naive (mild–severe); caution in INSTI-experienced with severe impairment (reduced levels)
Hepatic No adjustment mild–moderate (Child-Pugh A/B); not recommended in severe (C)
Available strengths
Pregnancy Pregnancy exposure registry; surveillance data do not show increased neural tube defects vs comparators; human data insufficient for definitive assessment
Lactation Undefined
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 5 mg | tab | 30 qd | — | not offered | |
| 50 mg | tab | 30 qd | — | $2,329.07 | not offered |
Available combined with: dolutegravir / lamivudine
Generic entry2030 est.
Open Dolutegravir in the interactive console ↗

Open Dolutegravir in the interactive console ↗